
Milton Nelson Jr.
Examiner (ID: 8060, Phone: (571)272-6861 , Office: P/3636 )
| Most Active Art Unit | 3636 |
| Art Unit(s) | 3624, 3636, 3507, 2899 |
| Total Applications | 4348 |
| Issued Applications | 3635 |
| Pending Applications | 235 |
| Abandoned Applications | 521 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 13717173
[patent_doc_number] => 20170369541
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-12-28
[patent_title] => METHODS TO PRODUCE ROD-DERIVED CONE VIABILITY FACTOR (RDCVF)
[patent_app_type] => utility
[patent_app_number] => 15/397455
[patent_app_country] => US
[patent_app_date] => 2017-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9599
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15397455
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/397455 | Methods to produce rod-derived cone viability factor (RDCVF) | Jan 2, 2017 | Issued |
Array
(
[id] => 13888173
[patent_doc_number] => 10196632
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-02-05
[patent_title] => Nucleic acid extraction using organic solvents to remove inhibitors
[patent_app_type] => utility
[patent_app_number] => 15/388973
[patent_app_country] => US
[patent_app_date] => 2016-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 5768
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 191
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15388973
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/388973 | Nucleic acid extraction using organic solvents to remove inhibitors | Dec 21, 2016 | Issued |
Array
(
[id] => 12023912
[patent_doc_number] => 20170314012
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-02
[patent_title] => 'MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/377846
[patent_app_country] => US
[patent_app_date] => 2016-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 32184
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15377846
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/377846 | Multi-chain eukaryotic display vectors and uses thereof | Dec 12, 2016 | Issued |
Array
(
[id] => 13618665
[patent_doc_number] => 20180360884
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-20
[patent_title] => IMMUNE CELL COMPOSITIONS AND METHODS OF USING SAME
[patent_app_type] => utility
[patent_app_number] => 16/060899
[patent_app_country] => US
[patent_app_date] => 2016-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38844
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -92
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16060899
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/060899 | Immune cell compositions and methods of using same | Dec 7, 2016 | Issued |
Array
(
[id] => 11979621
[patent_doc_number] => 20170283775
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-05
[patent_title] => 'Compositions and Methods for Treatment of Cancer'
[patent_app_type] => utility
[patent_app_number] => 15/353899
[patent_app_country] => US
[patent_app_date] => 2016-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 36979
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15353899
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/353899 | Compositions and Methods for Treatment of Cancer | Nov 16, 2016 | Abandoned |
Array
(
[id] => 11670058
[patent_doc_number] => 20170158779
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-06-08
[patent_title] => 'PROCESS AND METHODS FOR EFFICIENT MANUFACTURING OF HIGHLY PURE ASYMMETRIC ANTIBODIES IN MAMMALIAN CELLS'
[patent_app_type] => utility
[patent_app_number] => 15/355019
[patent_app_country] => US
[patent_app_date] => 2016-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 37
[patent_figures_cnt] => 37
[patent_no_of_words] => 22955
[patent_no_of_claims] => 45
[patent_no_of_ind_claims] => 9
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15355019
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/355019 | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells | Nov 16, 2016 | Issued |
Array
(
[id] => 16948135
[patent_doc_number] => 20210206826
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => CONDITIONALLY REPRESSIBLE IMMUNE CELL RECEPTORS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/777592
[patent_app_country] => US
[patent_app_date] => 2016-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41613
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15777592
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/777592 | CONDITIONALLY REPRESSIBLE IMMUNE CELL RECEPTORS AND METHODS OF USE THEREOF | Nov 16, 2016 | Abandoned |
Array
(
[id] => 13537173
[patent_doc_number] => 20180320133
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-08
[patent_title] => METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY
[patent_app_type] => utility
[patent_app_number] => 15/773807
[patent_app_country] => US
[patent_app_date] => 2016-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6645
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15773807
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/773807 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | Nov 3, 2016 | Abandoned |
Array
(
[id] => 17451890
[patent_doc_number] => 11266727
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-08
[patent_title] => Arenavirus particles as cancer vaccines
[patent_app_type] => utility
[patent_app_number] => 15/775360
[patent_app_country] => US
[patent_app_date] => 2016-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 11
[patent_no_of_words] => 48604
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 140
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15775360
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/775360 | Arenavirus particles as cancer vaccines | Nov 3, 2016 | Issued |
Array
(
[id] => 13537307
[patent_doc_number] => 20180320200
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-08
[patent_title] => Phagemid Vector
[patent_app_type] => utility
[patent_app_number] => 15/772961
[patent_app_country] => US
[patent_app_date] => 2016-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16236
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -49
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15772961
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/772961 | Phagemid vector | Oct 30, 2016 | Issued |
Array
(
[id] => 11568847
[patent_doc_number] => 20170107491
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-04-20
[patent_title] => 'CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE'
[patent_app_type] => utility
[patent_app_number] => 15/337854
[patent_app_country] => US
[patent_app_date] => 2016-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 34652
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15337854
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/337854 | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease | Oct 27, 2016 | Issued |
Array
(
[id] => 11691209
[patent_doc_number] => 20170166924
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-06-15
[patent_title] => 'METHODS FOR PRODUCING AND USING IN VIVO PSEUDOTYPED RETROVIRUSES'
[patent_app_type] => utility
[patent_app_number] => 15/334911
[patent_app_country] => US
[patent_app_date] => 2016-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 15660
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15334911
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/334911 | METHODS FOR PRODUCING AND USING IN VIVO PSEUDOTYPED RETROVIRUSES | Oct 25, 2016 | Abandoned |
Array
(
[id] => 18996191
[patent_doc_number] => 11913024
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-27
[patent_title] => Methods for culturing cells and kits and apparatus for same
[patent_app_type] => utility
[patent_app_number] => 15/770171
[patent_app_country] => US
[patent_app_date] => 2016-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 54
[patent_no_of_words] => 85904
[patent_no_of_claims] => 66
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 302
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15770171
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/770171 | Methods for culturing cells and kits and apparatus for same | Oct 19, 2016 | Issued |
Array
(
[id] => 19457907
[patent_doc_number] => 12098387
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-24
[patent_title] => Methods for generating engineered human primary blood dendritic cell lines
[patent_app_type] => utility
[patent_app_number] => 15/769241
[patent_app_country] => US
[patent_app_date] => 2016-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 41
[patent_figures_cnt] => 62
[patent_no_of_words] => 28397
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15769241
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/769241 | Methods for generating engineered human primary blood dendritic cell lines | Oct 18, 2016 | Issued |
Array
(
[id] => 18134765
[patent_doc_number] => 11560418
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-24
[patent_title] => Methods and compositions for modified factor IX fusion proteins
[patent_app_type] => utility
[patent_app_number] => 15/769252
[patent_app_country] => US
[patent_app_date] => 2016-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 4
[patent_no_of_words] => 10643
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15769252
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/769252 | Methods and compositions for modified factor IX fusion proteins | Oct 18, 2016 | Issued |
Array
(
[id] => 11986745
[patent_doc_number] => 20170290900
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-12
[patent_title] => 'CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS'
[patent_app_type] => utility
[patent_app_number] => 15/296666
[patent_app_country] => US
[patent_app_date] => 2016-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 11708
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15296666
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/296666 | CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS | Oct 17, 2016 | Abandoned |
Array
(
[id] => 13522661
[patent_doc_number] => 20180312873
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-01
[patent_title] => METHOD AND SYSTEMS FOR HIGH THROUGHPUT SINGLE CELL GENETIC MANIPULATION
[patent_app_type] => utility
[patent_app_number] => 15/769609
[patent_app_country] => US
[patent_app_date] => 2016-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16821
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15769609
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/769609 | METHOD AND SYSTEMS FOR HIGH THROUGHPUT SINGLE CELL GENETIC MANIPULATION | Oct 16, 2016 | Abandoned |
Array
(
[id] => 14069537
[patent_doc_number] => 20190083656
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-21
[patent_title] => METHODS AND COMPOSITIONS UTILIZING CPF1 FOR RNA-GUIDED GENE EDITING
[patent_app_type] => utility
[patent_app_number] => 15/768241
[patent_app_country] => US
[patent_app_date] => 2016-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20387
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15768241
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/768241 | METHODS AND COMPOSITIONS UTILIZING CPF1 FOR RNA-GUIDED GENE EDITING | Oct 13, 2016 | Abandoned |
Array
(
[id] => 17323774
[patent_doc_number] => 11214770
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-01-04
[patent_title] => Polar body injection
[patent_app_type] => utility
[patent_app_number] => 15/767045
[patent_app_country] => US
[patent_app_date] => 2016-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 2514
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 149
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15767045
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/767045 | Polar body injection | Sep 21, 2016 | Issued |
Array
(
[id] => 13672837
[patent_doc_number] => 20160375152
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-29
[patent_title] => METHODS AND COMPOSITIONS RELATING TO IMPROVED LENTIVIRAL VECTORS AND THEIR APPLICATIONS
[patent_app_type] => utility
[patent_app_number] => 15/263027
[patent_app_country] => US
[patent_app_date] => 2016-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23941
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15263027
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/263027 | Methods and compositions relating to improved lentiviral vectors and their applications | Sep 11, 2016 | Issued |